2 promising clinical stage assets, with one entering PH3 after approval from regulatory agencies. Eftilagimod alpha is an APC activator leveraging LAG-3’s ligand MHCII to increase both innate and adaptive immune response. This is a pan therapy, as in its benefit is across indications and in combination with any therapy causing tumor debris. This isn’t just a Keytruda enhancer, you’ll see.
2 promising clinical stage assets, with one entering PH3 after...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16911 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 154170 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |